Brief: Heat Biologics Announces Positive Interim Survival Data From Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial
09/02/2021 13:54
Feb 9 (Reuters) - Heat Biologics Inc HTBX.O :
* HEAT BIOLOGICS ANNOUNCES POSITIVE INTERIM SURVIVAL DATA
FROM
ONGOING HS-110 PHASE 2 NON-SMALL CELL LUNG CANCER TRIAL
* HEAT BIOLOGICS - MEDIAN OVERALL SURVIVAL OF 24.6 MONTHS IN
PREVIOUSLY TREATED CHECKPOINT INHIBITOR NAÏVE NSCLC PATIENTS WHO
GOT HS-110 WITH NIVOLUMAB
* HEAT BIOLOGICS - CURRENTLY EVALUATING POSSIBLE PHASE 3
REGISTRATION PATHWAYS FOR HS-110 IN COMBINATION WITH A
CHECKPOINT INHIBITOR
Source text: [ID: https://bit.ly/2N7HdVU]
Further company coverage: HTBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scorpius Holdings
See all newsBrief: Scorpius Holdings Inc Files For Non Timely 10-K With U.S. SEC
Brief: Scorpius Holdings Files For Offering Up To 29.4 Million Shares Of Common Stock
Brief: Scorpius Holdings Announces Collaboration With Celltheon Corporation
Brief: Scorpius Holdings - Implementation Of Strategic Cost-Saving Measures Expected To Save Over $2 Mln Annually
Brief: Scorpius Holdings Announces Partnership With U.S. Biotech Company